戊二醛交联对壳聚糖／羟基磷灰石-庆大霉素缓释材料性能的影响CSCD

背景:交联是骨组织工程材料改性的一种常用方法,但目前仍缺乏交联剂对载药人工骨材料性能影响的相关研究与报道。目的:研究戊二醛交联对壳聚糖/羟基磷灰石-庆大霉素载药人工骨材料力学性能、降解性能及体外药物缓释行为的影响。方法:分别制备壳聚糖质量分数为10%,20%,30%的壳聚糖/羟基磷灰石-庆大霉素载药人工骨材料与戊二醛交联壳聚糖/羟基磷灰石-庆大霉素载药人工骨材料,检测各组材料的机械强度、吸水率、降解率及体外药物释放行为。结果与结论:壳聚糖含量为10%,20%,30%壳聚糖/羟基磷灰石-庆大霉素的抗压强度分别为(10.16±1.17),(28.40±0.64),(23.28±1.30)MPa,经戊二醛交联后材料的抗压强度分别增大至(36.30±1.20),(51.60±2.08),(36.90±3.22)MPa。壳聚糖含量为10%,20%,30%壳聚糖/羟基磷灰石-庆大霉素交联后的吸水率与降解率均低于交联前。在体外缓释的第1天,30%壳聚糖/羟基磷灰石-庆大霉素的药物释放量为42.2%,材料经戊二醛交联处理后药物释放量降至33.6%,在随后的9 d,交联壳聚糖/羟基磷灰石-庆大霉素的总释放量均低于壳聚糖/羟基磷灰石-庆大霉素。表明戊二醛交联赋予了材料更好的生物稳定性,减缓了材料降解速率,显著改善了药物突释现象。     

壳聚糖微球/纳米羟基磷灰石/聚乳酸-羟基乙酸复合支架制备及其蛋白缓释效果:与单纯纳米羟基磷灰石/聚乳酸-羟基乙酸支架、壳聚糖微球的比较

背景:骨组织工程骨构建中如何使生长因子持续高效发挥作用是影响成骨速度和质量的关键,现多以各种材料的微球或支架作为缓释载体,但缓释作用有待提高。目的:实验拟制备壳聚糖微球,然后复合到纳米羟基磷灰石/聚乳酸-羟基乙酸支架上,形成双重缓释作用,并测量对牛血清白蛋白的释放效果。方法:以牛血清白蛋白为模型药物,采用乳化交联法制备壳聚糖微球。将微球与纳米羟基磷灰石、聚乳酸-羟基乙酸按一定比例混合,以冰粒子为致孔剂,采用冷冻干燥法制备壳聚糖微球/纳米羟基磷灰石/聚乳酸-羟基乙酸复合支架。利用扫描电镜、激光粒度分析仪、压泵仪和力学性能测试仪检测复合支架的形态性能,考察药物在缓释支架上的体外释放规律。结果与结论:所制备的壳聚糖微球形态良好,呈规则圆球形,粒径集中分布在20～40μm,微球药物包封率为86.5%,载药量为0.8%,随牛血清白蛋白初始用量的增加,载药量可升高至2.6%,但包封率下降至74.1%。壳聚糖微球能均匀分布在聚乳酸-羟基乙酸支架上,形成壳聚糖微球/纳米羟基磷灰石/聚乳酸-羟基乙酸复合支架,孔径为100～400μm,孔隙率80%,压缩强度为1.1～2.3MPa,10周降解率为26.5%。单纯纳米羟基磷灰石/聚乳酸-羟基乙酸支架其牛血清白蛋白在36h累积释放量达85%以上,壳聚糖微球其牛血清白蛋白10d累积释放量为33.6%,复合支架其牛血清白蛋白40d累积释放量为81.5%。结果证实包埋壳聚糖微球的纳米羟基磷灰石/聚乳酸-羟基乙酸支架其压缩强度和降解速率合适,对蛋白类药物具有良好的缓释作用,有望作为组织工程的支架材料和生长因子的缓释载体。     

长效缓释双药物人工骨的制备及释放特性

背景：利用可降解缓释生物材料包载利福平或异烟肼制成50 μm以下的缓释降解肺靶向微球已多有报道,主要用于静脉注射肺靶向治疗研究。 目的：研制长效缓释双组分药物人工骨,筛选最佳制备工艺并行体外释药特性观察。 方法：采用乳剂-溶剂挥发法正交设计优化制备工艺,分别制备利福平聚乳酸-羟基乙醇共聚物微球和异烟肼聚乳酸-羟基乙醇共聚物微球。利用生物黏合剂将两种微球加工成长效缓释双组分药物人工骨。 结果与结论：按照优化工艺分别制得聚乳酸-羟基乙醇共聚物载利福平26%、异烟肼28%的微球,并按质量各50%制成人工骨,体外释放90 d保持0.02,0.03 mg/L药物浓度。表明该人工骨有望为骨结核治疗用提供一种新型的方法。     

成骨生长肽壳聚糖-海藻酸钠微球的制备及体外检测

背景：成骨生长肽体外注射可以刺激外周血和骨髓细胞数增加,增加动物的骨量,加速骨折愈合,但因多肽不稳定性及注射应用不方便,限制了其临床应用。 目的：应用乳化交联法制备成骨生长肽壳聚糖-海藻酸钠缓释微球,并对其粒径、载药、体外释药、理化特性进行检测。 方法：以戊二醛作为交联剂,应用乳化交联法制备具有控制释放功能的负载成骨生长肽壳聚糖-海藻酸钠微球,显微镜及扫描电镜观察微球的形态和粒径;利用酶联免疫吸附实验动态检测成骨生长肽壳聚糖-海藻酸钠微球的载药率、包封率和缓释规律。 结果与结论：乳化交联法制备的壳聚糖-海藻酸钠微球,球形良好,球体表面有较多微孔,具有较高的包封率(>72%)。体外药物释放实验表明,成骨生长肽可以从壳聚糖-海藻酸钠微球中缓慢释放,整个释放过程可达49 d,累积释放率>85%。提示应用乳化交联法制备的负载成骨生长肽壳聚糖-海藻酸钠缓释微球,具有很好的控制释放成骨生长肽的能力。     

人同种异体骨载异烟肼-壳聚糖缓释微球的制备和体内外释药特性☆

背景：壳聚糖微球具有良好的生物相容性及抗菌活性,被广泛地运用于各种药物缓释系统中。 目的：制备人同种异体骨载异烟肼-壳聚糖微球,并分析其体内释药性能。 方法：用喷雾干燥法制备异烟肼-壳聚糖微球,进行体外45 d的药物释放实验。将单独装载异烟肼的异体骨块(对照组)和装载异烟肼-壳聚糖微球的异体骨块(实验组)分别植入家兔两侧髂骨,采用高效液相色谱法检测药物体内释放情况。 结果与结论：异烟肼-壳聚糖微球外观呈圆形、表面光滑、分散良好;平均粒径(3.33±0.9) μm,载药率(16.25±1.24)%。体外药物释放实验显示无突释现象,24 h释放20%左右,45 d释放76%,释放曲线较平缓,释放稳定;数学模型拟合符合Ritger-Peppas模型。实验组异烟肼浓度在前28 d内缓慢升高,其后缓慢下降,持续56 d以上,浓度38.50~155.75 µg/g;对照组异烟肼浓度在1周左右达高峰,为1982.5 µg/g,21 d后骨块周围药物不能测到。说明异烟肼-壳聚糖缓释微球在体内外均可以缓慢平稳释放异烟肼,且持续时间长。提示人同种异体骨载异烟肼-壳聚糖缓释微球复合体可以作为骨结核病灶清除后的一种置入材料,在提供机械支持的同时进行长时间的局部化疗。     

利福平/聚乳酸-聚羟基乙酸缓释微球的制备及特性

背景：虽然国内外有很多制备利福平/聚乳酸-聚羟基乙酸共聚物(poly lactic acid-glycolic acid copolymer,PLGA)微球的报道,但这些微球粒径多在10 μm左右,不适合与磷酸钙骨水泥复合制备成具有良好降解性的抗结核修复材料。 目的：制备大粒径利福平/PLGA缓释微球,观察其理化特性和体外缓释特性。 方法：以PLGA为载体,将利福平分散于PLGA的有机溶剂中,采用复乳溶剂挥发法制备利福平/ PLGA缓释微球。光镜和扫描电镜下观察微球的形态特征,测定微球平均直径和跨距,高效液相色谱法测定载药量和包封率,以溶出法和高效液相色谱法观察其体外释药特性,并拟合药物体外释放曲线建立曲线方程。 结果与结论：利福平/PLGA微球电镜观察呈圆球形,分散性好,粘连少,粒径分布集中,平均粒径(80.0±9.4) μm。载药量、包封率分别为(33.18±1.36)%,(54.79±1.13)%。体外缓释试验显示突释期内微球释放度为(14.66±0.18)%,前3 d累计释放度(18.09±0.45)%,到42 d体外累积释放度达到(92.17±1.23)%。提示利福平/PLGA微球具有良好的缓释效果,是一种较为理想的抗结核药物的载体材料和释放系统;PLGA是良好的药物缓释载体,可以用来制备载药缓释微球。     

壳聚糖-明胶/聚乳酸-羟基乙酸联合载药水凝胶的体外抗结核作用

文题释义：基质细胞衍生因子1：是一种参与免疫细胞活化、分化和迁移及伤口愈合、角膜上皮再生和组织修复等过程的趋化因子,能促进干细胞的生长和发育,参与调节成骨分化,可通过细胞归巢提高干细胞向病灶区的趋化作用。而基质细胞衍生因子1的失活会损害成骨细胞的发育和分化。此外,其还与血管生成密切相关。 异烟肼：具有较高的杀菌活性,是治疗结核病的一线药物。世卫组织建议将异烟肼作为结核病的标准疗法,用于潜伏性结核病感染者的预防治疗,与利福平、吡嗪酰胺和乙胺丁醇一起用于治疗活动性肺结核。异烟肼的活化形式与脂肪酸生物合成Ⅱ型系统中的NADH依赖型烯醇酰基载体蛋白还原酶异烟肼a结合,阻断细菌细胞壁关键成分支原体酸的合成。 背景：抗结核化疗是目前治疗骨关节结核的主要手段,然而全身给药难以维持病灶区的有效浓度,治疗效果欠佳。 目的：制备一种原位、长期释放抗结核药物且兼备促成骨作用的壳聚糖-明胶/聚乳酸-羟基乙酸联合载药水凝胶。 方法：将亲水性的抗结核药物异烟肼和疏水性的基质细胞衍生因子通过复乳法负载到聚乳酸-羟基乙酸中,制备聚乳酸-羟基乙酸载药微球,共混至壳聚糖-明胶水凝胶支架中,制备壳聚糖-明胶/聚乳酸-羟基乙酸联合载药水凝胶。检测聚乳酸-羟基乙酸载药微球、壳聚糖-明胶/聚乳酸-羟基乙酸联合载药水凝胶的体外释药与抗结核杆菌的能力。将成骨前体细胞MC3T3-E1分别接种于载药微球与联合载药水凝胶表面,CCK-8法检测细胞活力,碱性磷酸酶活性检测细胞的成骨性能。 结果与结论：①载药微球中异烟肼1 h内的突释约为23.3%,2 d内的释放率约为42.6%,随后进入缓释期,25 d后进入平台期;基质细胞衍生因子1在1 h内的累积释放率约为19.8%,2 d内的释放率约为44.7%,随后进入缓释期,25 d后进入平台期;联合载药水凝胶中异烟肼和基质细胞衍生因子1最初1 h的释放分别为8.3%和8.5%,第2天的累计释放率分别为15.2%和17.6%,远低于聚乳酸-羟基乙酸微球;②体外4周后,联合载药水凝胶的抑菌直径大于载药微球,抑菌率高于载药微球(P < 0.05);③联合载药水凝胶与载药微球均具有良好的细胞相容性,细胞活力均约为100%;④培养5,10 d后,联合载药水凝胶表面的细胞碱性磷酸酶活性与载药微球比较差异无显著性意义(P > 0.05);⑤结果表明,原位壳聚糖-明胶/聚乳酸-羟基乙酸联合载药水凝胶有作为治疗骨关节结核及其他骨关节感染的潜力。 ORCID: 0000-0003-4166-2492(张贺龙) 中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程     

京尼平交联仿骨结构诱导性骨组织工程支架材料的制备与表征

 背景：目前,尽管利用各种材料制备的组织工程化骨研究取得了一定进展,但均表现出诸如支架材料降解速度与新生骨组织形成速率不匹配、组织生长缓慢、降解代谢产物有毒性等缺陷。目的：构建一种新型的仿骨结构诱导性骨组织工程支架材料,评价其物理化学及生物学性能。方法：以壳聚糖包被淫羊藿苷制备微球,检测其体外缓释效果;将载药微球与胶原蛋白复合构建支架材料的管芯;将羟基磷灰石、聚己内酯与胶原蛋白依次以0∶3∶3、1∶3∶3、2∶3∶3、3∶3∶3的比例混合于六氟异丙醇中,通过静电纺丝技术依次电纺制得具有4层结构的支架材料外管;以1%京尼平将经嵌套的管芯与外管交联在一起。利用万能材料试验机、表面接触角仪、红外光谱、扫描电镜、吸水率、透气性、孔隙率、体外降解实验等对交联前后外管材料的结构和特征进行表征,并评价骨髓间充质干细胞与外管材料的生物相容性;Wistar大鼠皮下埋置实验进一步评价交联前后外管材料的组织相容性。结果与结论：药物在管芯中具有良好的缓释效果;制备的骨组织工程支架材料具有良好的均一性,交联后外管材料的力学性能、吸水率、透气性均高于未交联组(P < 0.05),且体外降解速率显著低于未交联组(P < 0.05)。苏木精-伊红染色显示骨髓间充质干细胞可良好贴附于交联前后的外管材料上;交联的外管材料植入Wistar大鼠皮下后均无炎症反应。表明交联后诱导性骨组织工程支架材料具有良好的生物相容性及力学性能。中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程     

3D打印成型纳米羟基磷灰石/壳聚糖/聚己内酯三元复合支架材料的构建及表征

文题释义： 组织工程骨：将体外培养的功能相关的种子细胞种植于天然的或人工合成的支架材料内,加入生长因子体外培养一段时间,将他们移植到体内,促进组织修复和骨再生的人工骨。组织工程骨形成的3要素为：支架材料、成骨细胞、生长因子。 生物陶瓷：生物表面活性陶瓷通常含有羟基,还可做成多孔性,生物组织可长入并同其表面发生牢固的键合;生物吸收性陶瓷的特点是能部分吸收或者全部吸收,在生物体内能诱发新生骨的生长。生物活性陶瓷具有骨传导性,它作为一个支架,成骨在其表面进行;还可作为多种物质的外壳或填充骨缺损。生物陶瓷有羟基磷灰石陶瓷、磷酸三钙陶瓷等。  背景：目前常用的骨缺损修复支架材料种类较多,但单一类型材料难以满足骨组织工程支架材料的要求,通过合适的方法将几种单一材料组合形成复合型材料,综合考虑各种材料优缺点,是近年来学者们的研究重点。 目的：构建纳米羟基磷灰石/壳聚糖/聚己内酯三元复合支架材料,并作表征分析研究。 方法：采用3D打印成型技术制备纳米羟基磷灰石/壳聚糖/聚己内酯多孔三元复合支架材料,从X射线衍射分析、吸水率、抗压强度、体外降解性能、孔径分析、扫描电镜分析等多个维度对支架材料进行表征研究。 结果与结论：①X射线衍射分析显示,纳米羟基磷灰石/壳聚糖/聚己内酯多孔三元复合支架的晶型峰图与羟基磷灰石粉末衍射标准卡片类似,表明该三元复合支架是通过物理作用相互结合的,不影响羟基磷灰石的生物学功能;②三元复合支架的吸水率为18.28%,亲水性好,支架可承受的最大压力为1 415 N,其体外降解速率与成骨速率相当;③显微镜下可见三元复合支架的内孔为方形,孔径250 µm,孔径大小均匀、分布有致;④扫描电镜下三元复合支架可见,壳聚糖和聚己内酯组成的纤维排列整齐有序,成网格状, 羟基磷灰石呈颗粒状在纤维表面均匀分布,三元复合材料呈现均匀、疏松的微孔结构;⑤结果表明,通过3D打印成型技术可成功制备纳米羟基磷灰石/壳聚糖/聚己内酯三元复合支架材料,其具有适度的抗压强度、一定的孔隙率、适宜的降解速度和吸水率,能为修复骨缺损的奠定基础。 ORCID: 0000-0002-6321-9160(余和东) 中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程       

聚乙二醇对利福平-聚乳酸-羟基乙酸聚合物缓释微球性能的影响

背景：聚乳酸-羟基乙酸共聚物微球具有良好的生物相容性,是优良的药物缓释载体,但缓释微球的突释问题严重影响了其临床应用。 目的：观察聚乙二醇对利福平-聚乳酸-羟基乙酸聚合物缓释微球特征、载药率、包封率、体外释放规律及突释的影响。 方法：以高分子材料聚乳酸-羟基乙酸共聚物作为载体,采用复乳化-溶剂挥发法制备聚乙二醇-利福平-聚乳酸-羟基乙酸聚合物微球(实验组)和利福平-聚乳酸-羟基乙酸聚合物微球(对照组)。扫描电子显微镜观察两组聚合物缓释微球特征,高效液相色谱法检测两组微球在不同时段模拟体液中的利福平药物浓度及累计释放量,计算两组微球的载药量、包封率。 结果与结论：与对照组比较,实验组微球表面光滑、粒径减小、分散良好,包封率和载药量明显提高。实验组微球3 h内药物释放量最大,1 d左右药物释放趋于平稳稳定状态,1 d药物累计释放量小于20%;对照组微球3 h内药物释放量最大,约为实验组的1.5倍,1 d左右药物释放也趋于平稳状态。表明聚乙二醇可改善利福平-聚乳酸-羟基乙酸聚合物缓释微球的成球率,减小其粒径,增加其载药量和包封率,控制其突释现象。 中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程全文链接：     

Physical,mechanical and degradation properties,and Schwann cell affinity of cross-linked chitosan films

Three kinds of cross-linked chitosan films were prepared with hexamethylene diisocyanate (HDI), epichlorohydrin (ECH) and glutaraldehyde (GA) as cross-linking agents, respectively. The physical and mechanical properties, biodegradability and Schwann cell affinity of the cross-linked films were investigated. A significant decrease in the degradation rate in lysozyme solution and a large change in the mechanical properties were observed compared with non-cross-linked chitosan films. The protein adsorption on chitosan films was determined by means of enzyme-linked immunosorbent assay (ELISA). In comparison with the non-cross-linked films, the chitosan films cross-linked with HDI showed a significant increase (up to 40–50%) in both fibronectin and laminin adsorption, while the protein adsorption on the other two kinds of cross-linked films was similar to that on non-cross-linked films. In addition, cell culture revealed that the HDI cross-linked chitosan films enhanced the spread and proliferation of Schwann cells while the other cross-linked films delayed the cell proliferation. These results suggest that HDI cross-linking of chitosan films provides a combination of physical properties, biodegradability and Schwann cell affinity suitable for peripheral nerve regeneration.     

Physical, mechanical and degradation properties, and schwann cell affinity of cross-linked chitosan films

Three kinds of cross-linked chitosan films were prepared with hexamethylene diisocyanate (HDI), epichlorohydrin (ECH) and glutaraldehyde (GA) as cross-linking agents, respectively. The physical and mechanical properties, biodegradability and Schwann cell affinity of the cross-linked films were investigated. A significant decrease in the degradation rate in lysozyme solution and a large change in the mechanical properties were observed compared with non-cross-linked chitosan films. The protein adsorption on chitosan films was determined by means of enzyme-linked immunosorbent assay (ELISA). In comparison with the non-cross-linked films, the chitosan films cross-linked with HDI showed a significant increase (up to 40-50%) in both fibronectin and laminin adsorption, while the protein adsorption on the other two kinds of cross-linked films was similar to that on non-crosslinked films. In addition, cell culture revealed that the HDI cross-linked chitosan films enhanced the spread and proliferation of Schwann cells while the other cross-linked films delayed the cell proliferation. These results suggest that HDI cross-linking of chitosan films provides a combination of physical properties, biodegradability and Schwann cell affinity suitable for peripheral nerve regeneration.     

壳聚糖微球复合丝素基硫酸钙骨水泥的理化特性

背景：脊柱成形和脊柱后凸成形治疗中采用的硫酸钙骨水泥理化性质好,对人体无毒性作用,同时具有降解性能,但单独使用降解较快。 目的：研制具有载药缓释功能的壳聚糖微球丝素基硫酸钙骨水泥。 方法：采用三聚磷酸钠乳化交联法制备壳聚糖微球。采用浓度分别为3%,6%,9%的丝素溶液与CaSO₄•0.5H₂O混合,通过万能力学试验机确定骨水泥力学性能最佳时的丝素浓度,在此浓度下,按壳聚糖微球占CaSO₄•0.5H₂O的质量比分别为0.5%,1%,5%的比例制备壳聚糖微球丝素基硫酸钙骨水泥,测定其抗压强度,并通过X射线多晶衍射仪及傅里叶红外光谱明确达到最佳抗压强度组的骨水泥成分,电镜观察复合骨水泥中壳聚糖微球的形态。 结果与结论：当丝素溶液浓度为6%,壳聚糖微球含量为0.5%时,复合骨水泥的抗压强度最大,为  (39.17±1.96) MPa,此时复合骨水泥的初凝时间为(12.99±1.63) min,终凝时间为(21.55±0.54) min;骨水泥中主要晶相组成为硫酸钙,傅里叶红外光谱结果证实复合骨水泥中含有丝素及壳聚糖;复合骨水泥中的微球表面稍有皱缩,但球形仍然完整,未见明显破坏,可见在制备复合骨水泥的过程中微球能保持稳定而不被破坏。中国组织工程研究杂志出版内容重点：生物材料;骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性;组织工程全文链接：     

载药人工骨研究的应用进展

背景：骨科药物缓释系统现已成为治疗骨科疾病的一大重要方法,作为其中之一的载药人工骨是目前新兴前沿的治疗手段。 目的：综述载药人工骨的分类及特点、研究方法和研究方向。 方法：由第一作者检索2001至2011年 PubMed数据库及维普外文期刊库有关载药人工骨材料分类、载药人工骨研究方法及载药人工骨应用研究等方面的文献。 结果与结论：载药人工骨主要分为羟基磷灰石、磷酸钙骨水泥、生物玻璃3类,前两者已逐步应用于临床研究及治疗中,生物玻璃是最近比较新的研究材料,在充当填充骨材料和药物释放载体上具有独特的功能,关于其特性、具体应用还要进一步研究。载药人工骨的研究方法主要从药物载体孔洞选择、人工骨制备、载药人工骨药物成分、人工骨药物释放机制等方面入手。载药人工骨具有药物载体和修复骨缺损的双重作用,且能诱导骨的生长和同步降解,具有操作简便,疗效好等优点,应用于骨髓炎、骨缺损和预防人工关节感染等方面是一种理想且有效的方法。     

复合重组人骨形态发生蛋白2壳聚糖缓释水凝胶的新型HA/ZrO2多孔泡沫陶瓷人工椎体修复犬脊椎骨缺损

目的 研制复合重组人骨形态发生蛋白2(rhBMP-2)壳聚糖水凝胶的新型HA/ZrO₂多孔泡沫陶瓷人工椎体,并观察其修复beagle犬椎体骨缺损的能力。方法 离子交联法制备壳聚糖水凝胶作为rhBMP-2的缓释载体,扫描电镜下观察其微观形态,检测其载药量、包封率及缓释速率。将HA/ZrO₂多孔泡沫陶瓷人工椎体复合rhBMP-2壳聚糖水凝胶,构建新型HA/ZrO₂多孔泡沫陶瓷人工椎体。将12只beagle犬按数字表法随机分为3组,每组4只;均采用手术造成半径9 mm、高23 mm的半圆柱状L₄椎骨缺损模型,其中A组植入复合rhBMP-2壳聚糖水凝胶的新型HA/ZrO₂多孔泡沫陶瓷人工椎体,B组植入复合空白干燥壳聚糖的新型HA/ZrO₂多孔泡沫陶瓷人工椎体,C组植入实验犬自体髂骨。术后6、12、24周对实验犬行大体观察、X线影像学观察;术后24周取实验犬椎体标本行离体Micro CT新生骨量检测及生物力学检测。结果 制备所得壳聚糖水凝胶扫描电镜下呈3D网状结构,内部均匀分布壳聚糖微球,其负载rhBMP-2后包封率达91.88%±1.53%,载药量为(39.84±2.34)ng/mg;释放率第1天为28.32%±3.01%,第3天为48.92%±6.27%,第12天为74.40%±6.29%。术后6周C组动物平均活动度恢复较A组和B组快(P值均＜0.05),A、B组差异无统计学意义(P＞0.05);术后12、24周B组与C组活动度比较差异均有统计学意义(P值均＜0.05),A、C组差异均无统计学意义(P值均＞0.05)。术后6、12、24周X线影像学观察显示,A组椎体置换术后骨痂生成逐渐增多,植入材料与宿主骨之间的界线逐渐模糊,至24周时人工椎体周围新生骨与自体骨融为一体;C组在24周时出现明显非承重部位的骨吸收,出现较快的自体骨塑形;B组椎体置换术后人工椎体与自体骨的融合速度慢于A组和C组。术后24周标本Micro CT新生骨量检测结果显示,A组(145.38±18.52)mm³,B组(86.30±15.60)mm³,两组比较差异有统计学意义(t=4.879, P＜0.01)。术后24周A、B、C组手术节段椎体标本抗压强度分别为(14.03±1.67) MPa、(8.62±1.24) MPa、(13.79±1.43) MPa,A组和C组椎体极限抗压强度均高于B组(P值均＜0.01),而A组与C组比较差异无统计学意义(P＞0.05)。结论 复合rhBMP-2壳聚糖水凝胶新型HA/ZrO₂多孔泡沫陶瓷人工椎体能有效修复脊柱骨缺损,有望代替自体髂骨移植运用于临床骨缺损的修复。     

Novel soy protein wound dressings with controlled antibiotic release: mechanical and physical properties

Naturally derived materials are becoming widely used in the biomedical field. Soy protein has advantages over various types of natural proteins employed for biomedical applications due to its low price, non-animal origin and relatively long storage time and stability. In the current study soy protein isolate (SPI) was investigated as a matrix for wound dressing applications. The antibiotic drug gentamicin was incorporated into the matrix for local controlled release and, thus, protection against bacterial infection. Homogeneous yellowish films were cast from aqueous solutions. After cross-linking they combined high tensile strength and Young’s modulus with the desired ductility. The plasticizer type, cross-linking agent and method of cross-linking were found to strongly affect the tensile properties of the SPI films. Selected SPI films were tested for relevant physical properties and the gentamicin release profile. The cross-linking method affected the degree of water uptake and the weight loss profile. The water vapor transmission rate of the films was in the desired range for wound dressings (∼2300 g m⁻² day⁻¹) and was not affected by the cross-linking method. The gentamicin release profile exhibited a moderate burst effect followed by a decreasing release rate which was maintained for at least 4 weeks. Diffusion was the dominant release mechanism of gentamicin from cross-linked SPI films. Appropriate selection of the process parameters yielded SPI wound dressings with the desired mechanical and physical properties and drug release behavior to protect against bacterial infection. These unique structures are thus potentially useful as burn and ulcer dressings.     

Modified n-HA/PA66 scaffolds with chitosan coating for bone tissue engineering: cell stimulation and drug release

The dipping-drying procedure and cross-linking method were used to make drug-loaded chitosan (CS) coating on nano-hydroxyapatite/polyamide66 (nHA/PA66) composite porous scaffold, endowing the scaffold controlled drug release functionality. The prefabricated scaffold was immersed into an aqueous drug/CS solution in a vacuum condition and then crosslinked by vanillin. The structure, porosity, composition, compressive strength, swelling ratio, drug release and cytocompatibility of the pristine and coating scaffolds were investigated. After coating, the scaffold porosity and pore interconnection were slightly decreased. Cytocompatibility performance was observed through an in vitro experiment based on cell attachment and the MTT assay by MG63 cells which revealed positive cell viability and increasing proliferation over the 11-day period in vitro. The drug could effectively release from the coated scaffold in a controlled fashion and the release rate was sustained for a long period and highly dependent on coating swelling, suggesting the possibility of a controlled drug release. Our results demonstrate that the scaffold with drug-loaded crosslinked CS coating can be used as a simple technique to render the surfaces of synthetic scaffolds active, thus enabling them to be a promising high performance biomaterial in bone tissue engineering.     

Cross-linking of amniotic membranes

Human amniotic membrane was cross-linked with chemical and radiation methods to investigate the effect of cross-linking on its physicochemical and biodegradation properties. Radiation cross-linking was performed with gamma-ray and electron beam while chemical cross-linking was with glutaraldehyde (GA). Both gamma-ray and electron beam irradiation decreased the tensile strength and elongation at break of the amniotic membrane with an increase in the irradiation dose, whereas GA cross-linking had no effect on the tensile properties. This is probably due to the scission of collagen chains through irradiation. No significant change was observed on the water content of cross-linked amniotic membranes for any of the crosslinking methods and in marked contrast with cross-linking of a gelatin membrane. A permeation study revealed that protein permeation through the amniotic membrane was not influenced by the GA concentration at cross-linking. These findings are ascribed to the structure characteristic of the amniotic membrane. The membrane is composed of a fibrous mesh structure from an assemblage of collagen fibers. It is possible that cross-linking takes place in the interior of the fiber assembly without impairing the mesh structure, resulting in no change of the water content and protein permeability. In vitro degradation of cross-linked amniotic membranes revealed that radiation cross-linking appeared to be much less effective than GA cross-linking in retarding the degradation, probably because of low cross-linking densities. GA-cross-linked amniotic membranes were degraded more slowly as the GA concentration at cross-linking increased. When the GA-cross-linked amniotic membrane was subcutaneously implanted in the rat, the tissue response was mild, similar to that of the non-cross-linked native membrane.     

Degradation behaviour of self-reinforced 80L/20G PLGA devices in vitro

In vitro degradation of self-reinforced PLGA 80L/20G material and bioabsorbable stents was studied in artificial urine and phosphate buffer solution (PBS) to define if the media have an effect on the degradation rate in urological applications. After six weeks, the Mv of the samples immersed in PBS was 40% (16.7 kDa) from the initial value and 57% (24.0 kDa) for the samples immersed in artificial urine. The strength loss of samples that were immersed in PBS was slower when compared with samples in artificial urine. The bending strength of samples immersed 15 weeks in artificial urine was 43% (21.7 MPa) of the bending strength of samples immersed in PBS (50.9 MPa), and the shear strength was 13% (artificial urine 3.7 MPa, PBS 28.8 MPa), respectively. The maximum compression force in PBS was slightly over at the initial level after 2 weeks of immersion. It decreased to half (102.2N) of the initial value (204.1N) in 8 weeks, and after 12 weeks it was 25% (50.8 N) of the initial value. The compression force in artificial urine was 35% (66.8 N) of the initial value (193.9 N) after 8 weeks. In 12 weeks it had lowered to 26 N in artificial urine, which was 14% of the initial value. The degradation rate of self-reinforced L-lactic and glycolic acid stents in vitro tests in artificial urine was coinciding with our clinical test. Based on these results, it is possible to make a sufficiently accurate in vitro model for the degradation rate of bioabsorbable polymers for urological applications.